<DOC>
	<DOCNO>NCT02694588</DOCNO>
	<brief_summary>Inflammatory bowel disease ( IBD ) psoriasis ( Ps ) common , chronic , immune- mediate barrier disease share inflammatory pathway . Current therapeutic intervention anti-cytokine antibody ( TNF-Î± , IL-23/IL-12 ) reflect intent disrupt specific pathways inflammatory immunopathology . Individual response biological treatment thereby exploit system biology approach employ targeted mechanism action ( MOA ) decipher molecular signature therapeutic response context distinct disease entity . Using translational approach investigate clinical molecular phenotype therapeutic interference cytokine signal leukocyte trafficking , investigator aim trace common unique signature drug- therapy-specific response . Patients undergo endoscopic evaluation mucosal surface gastrointestinal wall conventional HD-colonoscopy , endoscopic ultrasound confocal laser endomicroscopy prior specific therapy biologicals . In parallel , mucosa sample obtain define molecular phenotype course therapy .</brief_summary>
	<brief_title>Clinical Molecular Phenotyping IBD</brief_title>
	<detailed_description />
	<mesh_term>Vedolizumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>inflammatory bowel disease indication biological therapy pregnancy , breast feeding write informed consent participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Vedolizumab</keyword>
	<keyword>Infliximab</keyword>
</DOC>